Dosing Frequency for Intravenous L-Ornithine L-Aspartate (LOLA)
For hepatic encephalopathy in adults, intravenous L-ornithine L-aspartate should be administered as 30 g/day as a continuous infusion over 24 hours. 1
Clinical Context and Administration
The 2020 KASL guidelines for liver cirrhosis specifically recommend 30 g/day of intravenous LOLA for managing overt hepatic encephalopathy 1. This is administered as a single daily dose given continuously over 24 hours, not as divided doses throughout the day.
Evidence for Efficacy
When combined with lactulose, this dosing regimen demonstrated:
- Lower grades of hepatic encephalopathy within 1-4 days (OR: 2.06-3.04)
- Shorter duration until symptom recovery (1.92 vs 2.50 days, p=0.002) compared to lactulose alone 1
The mechanism works through ornithine and aspartate serving as substrates to metabolize ammonia to urea and glutamine, thereby lowering plasma ammonia concentrations 1.
Important Distinctions
Do not confuse LOLA with L-arginine, which has entirely different indications and dosing:
- L-arginine hydrochloride for hyperammonemia in urea cycle disorders is dosed as a 90-minute bolus followed by continuous maintenance over 24 hours 2
- L-arginine for diagnostic testing (growth hormone stimulation) is given as a single 30-minute infusion 3
Clinical Pearls
- LOLA is most effective for West-Haven criteria grade 1-2 hepatic encephalopathy 1
- The continuous 24-hour infusion maintains steady plasma levels for optimal ammonia metabolism
- Oral LOLA formulations exist but require further study for efficacy in overt hepatic encephalopathy 1
- Maximum treatment duration is typically 10 days or until clinical improvement 1